Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Risk of cytomegalovirus transmission by blood products after solid organ transplantation.

Jebakumar D, Bryant P, Linz W.

Proc (Bayl Univ Med Cent). 2019 Apr 23;32(2):222-226. doi: 10.1080/08998280.2019.1582932. eCollection 2019 Apr. Review.

2.

Monitoring hemodynamic changes in stroke-affected muscles using near-infrared spectroscopy.

MasoudiMotlagh M, Sugar JJ, Azimipour M, Linz WW, Michalak G, Seo NJ, Ranji M.

J Rehabil Assist Technol Eng. 2015 Oct 29;2:2055668315614195. doi: 10.1177/2055668315614195. eCollection 2015 Jan-Dec.

3.

Discovery and pharmacological characterization of a novel potent inhibitor of diacylglycerol-sensitive TRPC cation channels.

Maier T, Follmann M, Hessler G, Kleemann HW, Hachtel S, Fuchs B, Weissmann N, Linz W, Schmidt T, Löhn M, Schroeter K, Wang L, Rütten H, Strübing C.

Br J Pharmacol. 2015 Jul;172(14):3650-60. doi: 10.1111/bph.13151. Epub 2015 May 19.

4.

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.

Wohlfart P, Linz W, Hübschle T, Linz D, Huber J, Hess S, Crowther D, Werner U, Ruetten H.

J Transl Med. 2013 Mar 28;11:84. doi: 10.1186/1479-5876-11-84.

5.

Inhibition of CatA: an emerging strategy for the treatment of heart failure.

Ruf S, Buning C, Schreuder H, Linz W, Hübschle T, Linz D, Ruetten H, Wirth K, Sadowski T.

Future Med Chem. 2013 Mar;5(4):399-409. doi: 10.4155/fmc.13.24.

PMID:
23495688
6.

American Society for Apheresis white paper: considerations for medical staff apheresis medicine physician credentialing and privileging.

Andrzejewski C Jr, Linz W, Hofmann J, O'Doherty U, Robinson RS, Arepally GM, Golden P.

J Clin Apher. 2012;27(6):330-5. doi: 10.1002/jca.21250. Epub 2012 Nov 2.

PMID:
23124963
7.

Antihypertensive and laxative effects by pharmacological inhibition of sodium-proton-exchanger subtype 3-mediated sodium absorption in the gut.

Linz D, Wirth K, Linz W, Heuer HO, Frick W, Hofmeister A, Heinelt U, Arndt P, Schwahn U, Böhm M, Ruetten H.

Hypertension. 2012 Dec;60(6):1560-7. doi: 10.1161/HYPERTENSIONAHA.112.201590. Epub 2012 Oct 29.

PMID:
23108657
8.

Cardiac remodeling and myocardial dysfunction in obese spontaneously hypertensive rats.

Linz D, Hohl M, Mahfoud F, Reil JC, Linz W, Hübschle T, Juretschke HP, Neumann-Häflin C, Rütten H, Böhm M.

J Transl Med. 2012 Sep 10;10:187. doi: 10.1186/1479-5876-10-187.

9.

Novel β-amino acid derivatives as inhibitors of cathepsin A.

Ruf S, Buning C, Schreuder H, Horstick G, Linz W, Olpp T, Pernerstorfer J, Hiss K, Kroll K, Kannt A, Kohlmann M, Linz D, Hübschle T, Rütten H, Wirth K, Schmidt T, Sadowski T.

J Med Chem. 2012 Sep 13;55(17):7636-49. doi: 10.1021/jm300663n. Epub 2012 Aug 16.

PMID:
22861813
10.

Should we establish a new protocol for the treatment of peripartum myocardial infarction?

Houck PD, Strimel WJ, Gantt DS, Linz WJ.

Tex Heart Inst J. 2012;39(2):244-8.

11.

AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.

Schäfer HL, Linz W, Falk E, Glien M, Glombik H, Korn M, Wendler W, Herling AW, Rütten H.

Acta Pharmacol Sin. 2012 Jan;33(1):82-90. doi: 10.1038/aps.2011.165.

12.

[Manual therapy for insertional tendinosis].

Müller R, Linz W, Buchmann J.

MMW Fortschr Med. 2011 Jan 13;153(1-2):34-5. Review. German. No abstract available.

PMID:
24761489
13.

[Concept of treatment of low back pain].

Müller R, Linz W, Buchmann J.

MMW Fortschr Med. 2011 Jan 13;153(1-2):31-3. Review. German. No abstract available.

PMID:
24761488
14.
15.

[Manual medicine handcraft, medicine enchantment?].

Müller R, Linz W.

MMW Fortschr Med. 2011 Jan 13;153(1-2):26. German. No abstract available.

PMID:
24761486
16.
17.

Transfusion med illustrated. Retrograde transmission of Enterobacter cloacae during blood transfusion confirmed by pulsed-field gel electrophoresis.

Linz W, Fader R, Smith D.

Transfusion. 2010 May;50(5):968-9. doi: 10.1111/j.1537-2995.2010.02613.x. No abstract available.

PMID:
20546549
18.

Multivessel myocardial infarction: a window to future treatments of myocardial infarction.

Houck PD, Linz WJ.

Heart Asia. 2010 Aug 26;2(1):82-8. doi: 10.1136/ha.2009.001545. eCollection 2010. No abstract available.

19.

Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor.

Löhn M, Plettenburg O, Ivashchenko Y, Kannt A, Hofmeister A, Kadereit D, Schaefer M, Linz W, Kohlmann M, Herbert JM, Janiak P, O'Connor SE, Ruetten H.

Hypertension. 2009 Sep;54(3):676-83. doi: 10.1161/HYPERTENSIONAHA.109.134353. Epub 2009 Jul 13.

PMID:
19597037
20.

The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats.

Linz W, Wohlfart P, Baader M, Breitschopf K, Falk E, Schäfer HL, Gerl M, Kramer W, Rütten H.

Acta Pharmacol Sin. 2009 Jul;30(7):935-46. doi: 10.1038/aps.2009.58. Epub 2009 Jun 8.

21.

Inhibition of renin angiotensin system decreases renal protein oxidative damage in diabetic rats.

Portero-Otín M, Pamplona R, Boada J, Jové M, Gonzalo H, Buleon M, Linz W, Schäfer S, Tack I, Girolami JP.

Biochem Biophys Res Commun. 2008 Apr 11;368(3):528-35. doi: 10.1016/j.bbrc.2008.01.101. Epub 2008 Feb 1.

PMID:
18243127
22.

Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage.

Benz K, Orth SR, Simonaviciene A, Linz W, Schindler U, Rütten H, Amann K.

Kidney Blood Press Res. 2007;30(4):224-33. Epub 2007 Jun 15.

23.

Detailed documentation of one lipolysis treatment: blood values, histology, and ultrasound findings.

Hasengschwandtner F, Furtmueller F, Spanbauer M, Silye R, Linz WJ.

Aesthet Surg J. 2007 Mar-Apr;27(2):204-11. doi: 10.1016/j.asj.2007.01.010.

PMID:
19341647
24.

Decreased wheel-running activity in hamsters post myocardial infarction.

Schäfer S, Linz W, Hürland K.

J Transl Med. 2006 Dec 2;4:51.

25.

Vasopeptidase inhibition prevents target organ damage and improves survival in spontaneously hypertensive rats.

Linz W, Schäfer S, Afkham F, Gerl M, Schmidts HL, Rütten H.

J Renin Angiotensin Aldosterone Syst. 2006 Sep;7(3):155-61.

PMID:
17094052
26.

Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase.

Schindler U, Strobel H, Schönafinger K, Linz W, Löhn M, Martorana PA, Rütten H, Schindler PW, Busch AE, Sohn M, Töpfer A, Pistorius A, Jannek C, Mülsch A.

Mol Pharmacol. 2006 Apr;69(4):1260-8. Epub 2005 Dec 6.

PMID:
16332991
27.

Impaired left ventricular relaxation in type 2 diabetic rats is related to myocardial accumulation of N(epsilon)-(carboxymethyl) lysine.

Schäfer S, Huber J, Wihler C, Rütten H, Busch AE, Linz W.

Eur J Heart Fail. 2006 Jan;8(1):2-6. Epub 2005 Aug 8. Erratum in: Eur J Heart Fail. 2006 Oct;8(6):662.

28.

Ramipril prevents extracellular matrix accumulation in cerebral microvessels.

Liebetrau M, Burggraf D, Büscher C, Linz W, Hamann GF.

Neurol Res. 2005 Jul;27(5):477-82.

PMID:
16025600
29.

The isolated working heart model in infarcted rat hearts.

Itter G, Jung W, Schoelkens BA, Linz W.

Lab Anim. 2005 Apr;39(2):178-93.

PMID:
15901361
30.

Restoration of endothelial function via enhanced nitric oxide synthesis after long-term treatment of raloxifene in adult hypertensive rats.

Leitzbach D, Weckler N, Madajka M, Malinski T, Wiemer G, Linz W.

Arzneimittelforschung. 2005;55(2):86-92.

PMID:
15787275
31.

ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats.

Liebetrau M, Burggraf D, Wunderlich N, Jäger G, Linz W, Hamann GF.

Neurosci Lett. 2005 Mar 16;376(3):205-9. Epub 2004 Dec 31.

PMID:
15721222
32.

Down-regulation of calpain 9 is linked to hypertensive heart and kidney disease.

Markmann A, Schäfer S, Linz W, Löhn M, Busch AE, Wohlfart P.

Cell Physiol Biochem. 2005;15(1-4):109-16.

33.

Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent.

Schäfer S, Schmidts HL, Bleich M, Busch AE, Linz W.

Br J Pharmacol. 2004 Sep;143(1):27-32. Epub 2004 Aug 2.

34.
35.

A model of chronic heart failure in spontaneous hypertensive rats (SHR).

Itter G, Jung W, Juretschke P, Schoelkens BA, Linz W.

Lab Anim. 2004 Apr;38(2):138-48.

PMID:
15070453
36.

Chronic vasopeptidase inhibition normalizes diabetic endothelial dysfunction.

Schäfer S, Steioff K, Linz W, Bleich M, Busch AE, Löhn M.

Eur J Pharmacol. 2004 Jan 26;484(2-3):361-2.

PMID:
14744624
37.

The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy.

Schäfer S, Linz W, Vollert H, Biemer-Daub G, Rütten H, Bleich M, Busch AE.

Diabetologia. 2004 Jan;47(1):98-103. Epub 2003 Nov 14.

PMID:
14618238
38.

Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile.

Zhu YZ, Wang ZJ, Zhu YC, Zhang L, Oakley RM, Chung CW, Lim KW, Lee HS, Ozoux ML, Linz W, Böhm M, Kostenis E.

Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H830-6. Epub 2003 Nov 13.

39.

Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats.

Schäfer S, Linz W, Bube A, Gerl M, Huber J, Kürzel GU, Bleich M, Schmidts HL, Busch AE, Rütten H.

Cardiovasc Res. 2003 Nov 1;60(2):447-54.

PMID:
14613875
40.

Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits.

Weckler N, Leitzbach D, Kalinowski L, Malinski T, Busch AE, Linz W.

J Renin Angiotensin Aldosterone Syst. 2003 Sep;4(3):191-6. Erratum in: J Renin Angiotensin Aldosterone Syst. 2004 Jun;5(2):58. Kalinowki, Ludmila [corrected to Kalinowski, Leszek].

PMID:
14608526
41.

Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction.

Linz W, Itter G, Dobrucki LW, Malinski T, Wiemer G.

J Renin Angiotensin Aldosterone Syst. 2003 Sep;4(3):180-5.

PMID:
14608524
42.

NHE-1 inhibition: from protection during acute ischaemia/reperfusion to prevention/reversal of myocardial remodelling.

Linz WJ, Busch AE.

Naunyn Schmiedebergs Arch Pharmacol. 2003 Oct;368(4):239-46. Epub 2003 Sep 19. Review.

PMID:
14504689
43.

Transfusion medicine illustrated: cold agglutinin disease.

Linz WJ, Tauscher C, Winters JL, Gastineau DA, Moore B.

Transfusion. 2003 Sep;43(9):1185. No abstract available.

PMID:
12919418
44.
45.

Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats.

Seeland U, Kouchi I, Zolk O, Jockenhövel F, Itter G, Linz W, Böhm M.

Eur J Heart Fail. 2003 Jun;5(3):241-6.

46.

Transfusion medicine illustrated. Lack of effect of 2 M urea on Jk(a-b-) cells.

Linz WJ, Muenster S, Watkins J, Moore SB.

Transfusion. 2003 Jun;43(6):685. No abstract available.

PMID:
12757514
47.

Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats.

Hropot M, Langer KH, Wiemer G, Grötsch H, Linz W.

Naunyn Schmiedebergs Arch Pharmacol. 2003 Mar;367(3):312-7. Epub 2003 Jan 25.

PMID:
12644905
48.

[Intervention in the renin-angiotensin and kallikrein-kinin systems. Pharmacologic basis of the action of ACE inhibitors].

Linz W, Busch AE.

Pharm Unserer Zeit. 2003;32(1):18-22. Review. German. No abstract available.

PMID:
12577756
49.

Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production.

Wassmann S, Laufs U, Stamenkovic D, Linz W, Stasch JP, Ahlbory K, Rösen R, Böhm M, Nickenig G.

Circulation. 2002 Apr 30;105(17):2083-91.

PMID:
11980689
50.

Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts.

Seeland U, Kouchi I, Zolk O, Itter G, Linz W, Böhm M.

J Mol Cell Cardiol. 2002 Feb;34(2):151-63.

PMID:
11851355

Supplemental Content

Support Center